{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:40:34Z","timestamp":1791290434115,"version":"4.3.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI027757"],"award-info":[{"award-number":["AI027757"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Patient preferences for long-acting antiretroviral therapies (LA-ART) should inform development of regimens with optimal adherence and acceptability. We describe a systematic process used to identify attributes and levels for a discrete choice experiment (DCE) designed to elicit preferences for potential LA-ART options in the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our approach was conducted in four stages: data collection, data reduction, removing inappropriate attributes, and optimizing wording. We started with 8 attributes defining potential LA-ART products based on existing literature and knowledge of products in development. We conducted 12 key informant interviews with experts in HIV treatment. The list of attributes, the set of plausible levels for each attribute, and restrictions on combinations of attribute levels were updated iteratively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Despite uncertainty about which products will become available, key informant discussions converged on 4 delivery modes (infusions and patches were not considered immediately feasible) and 6 additional attributes. Treatment effectiveness and frequency of clinical monitoring were dropped. Oral lead-in therapy was split into two attributes: pre-treatment time undetectable and pre-treatment negative reaction testing. We omitted product-specific systemic and local side effects. In addition to mode, the final set of attributes included: frequency of dosing; location of treatment; pain; pre-treatment time undetectable; pre-treatment negative reaction testing; and late-dose leeway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A systematic process successfully captured elements that are both feasible and relevant to evaluating the acceptability of potential LA-ART alternatives to patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-022-00435-6","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T11:03:11Z","timestamp":1645786991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-7159","authenticated-orcid":false,"given":"Aaron T.","family":"Brah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Barthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Hauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C.","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J. Y.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C.","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Simoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"435_CR1","doi-asserted-by":"publisher","first-page":"205031211881691","DOI":"10.1177\/2050312118816919","volume":"6","author":"SN Kapadia","year":"2018","unstructured":"Kapadia SN, et al. HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens. SAGE Open Med. 2018;6:2050312118816919.","journal-title":"SAGE Open Med."},{"key":"435_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.addr.2016.02.003","volume":"103","author":"A Owen","year":"2016","unstructured":"Owen A, Rannard S. Strengths, weaknesses, opportunities and challenges for long-acting injectable therapies: insights for applications in HIV therapy. Adv Drug Deliv Rev. 2016;103:144\u201356.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"435_CR3","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3018(18)30102-4","volume":"5","author":"RS Hogg","year":"2018","unstructured":"Hogg RS. Understanding the HIV care continuum. Lancet HIV. 2018;5(6):e269\u201370.","journal-title":"Lancet HIV"},{"issue":"10101","key":"435_CR4","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"390","author":"DA Margolis","year":"2017","unstructured":"Margolis DA, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499\u2013510.","journal-title":"Lancet"},{"issue":"1","key":"435_CR5","doi-asserted-by":"publisher","first-page":"e0190487","DOI":"10.1371\/journal.pone.0190487","volume":"13","author":"D Kerrigan","year":"2018","unstructured":"Kerrigan D, et al. Experiences with long-acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of cabotegravir+ rilpivirine (LATTE-2) in the United States and Spain. PLoS ONE. 2018;13(1):e0190487.","journal-title":"PLoS ONE"},{"issue":"4","key":"435_CR6","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s10461-017-1871-x","volume":"22","author":"K Meyers","year":"2018","unstructured":"Meyers K, et al. Lessons for patient education around long-acting injectable PrEP: findings from a mixed-method study of phase II trial participants. AIDS Behav. 2018;22(4):1209\u201316.","journal-title":"AIDS Behav"},{"issue":"11","key":"435_CR7","doi-asserted-by":"publisher","first-page":"e1002690","DOI":"10.1371\/journal.pmed.1002690","volume":"15","author":"RJ Landovitz","year":"2018","unstructured":"Landovitz RJ, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15(11):e1002690.","journal-title":"PLoS Med"},{"issue":"3","key":"435_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1089\/apc.2018.0198","volume":"33","author":"JM Simoni","year":"2019","unstructured":"Simoni JM, et al. Long-acting injectable antiretroviral treatment acceptability and preferences: a qualitative study among US providers, adults living with HIV, and parents of youth living with HIV. AIDS Patient Care STDs. 2019;33(3):104\u201311.","journal-title":"AIDS Patient Care STDs"},{"issue":"4","key":"435_CR9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s10461-019-02701-7","volume":"24","author":"JM Simoni","year":"2020","unstructured":"Simoni JM, et al. A conjoint analysis of the acceptability of targeted long-acting injectable antiretroviral therapy among persons living with HIV in the US. AIDS Behav. 2020;24(4):1226\u201336.","journal-title":"AIDS Behav"},{"issue":"6","key":"435_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3109\/14659891.2015.1118563","volume":"21","author":"TM Helter","year":"2016","unstructured":"Helter TM, Boehler CE. Developing attributes for discrete choice experiments in health: a systematic literature review and case study of alcohol misuse interventions. J Subst Use. 2016;21(6):662\u20138.","journal-title":"J Subst Use."},{"issue":"8","key":"435_CR11","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1007\/s10461-018-02387-3","volume":"23","author":"JM Simoni","year":"2019","unstructured":"Simoni JM, Beima-Sofie K, Amico KR, Hosek SG, Johnson MO, Mensch BS. Debrief reports to expedite the impact of qualitative research: do they accurately capture data from in-depth interviews? AIDS Behav. 2019;23(8):2185\u20139.","journal-title":"AIDS Behav"},{"issue":"8","key":"435_CR12","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1007\/s10461-018-2078-5","volume":"22","author":"AM Minnis","year":"2018","unstructured":"Minnis AM, Roberts ST, Agot K, Weinrib R, Ahmed K, Manenzhe K, van der OwinoStraten FA. Young women\u2019s ratings of three placebo multipurpose prevention technologies for HIV and pregnancy prevention in a randomized, cross-over study in Kenya and South Africa. AIDS Behav. 2018;22(8):2662\u201373.","journal-title":"AIDS Behav"},{"issue":"4","key":"435_CR13","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1007\/s10461-017-1851-1","volume":"22","author":"R Shrestha","year":"2018","unstructured":"Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T, Copenhaver M. Measuring acceptability and preferences for implementation of pre-exposure prophylaxis (PrEP) using conjoint analysis: an application to primary HIV prevention among high risk drug users. AIDS Behav. 2018;22(4):1228\u201338.","journal-title":"AIDS Behav"},{"issue":"2","key":"435_CR14","first-page":"75","volume":"40","author":"S Rusconi","year":"2017","unstructured":"Rusconi S, Marcotullio S, Cingolani A. Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient\u2019s perspective. New Microbiol. 2017;40(2):75\u20139.","journal-title":"New Microbiol"},{"key":"435_CR15","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.2147\/PPA.S114172","volume":"10","author":"EG Katz","year":"2016","unstructured":"Katz EG, Hauber B, Gopal S, Fairchild A, Pugh A, Weinstein RB, Levitan BS. Physician and patient benefit\u2013risk preferences from two randomized long-acting injectable antipsychotic trials. Patient Prefer Adherence. 2016;10:2127.","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"435_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1176\/appi.ps.201400188","volume":"66","author":"B Levitan","year":"2015","unstructured":"Levitan B, Markowitz M, Mohamed AF, Johnson FR, Alphs L, Citrome L, Bridges JF. Patients\u2019 preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatr Serv. 2015;66(7):719\u201326.","journal-title":"Psychiatr Serv"},{"issue":"3","key":"435_CR17","doi-asserted-by":"publisher","first-page":"e25094","DOI":"10.1002\/jia2.25094","volume":"21","author":"A van der Straten","year":"2018","unstructured":"van der Straten A, Agot K, Ahmed K, Weinrib R, Browne EN, Manenzhe K, Owino F, Schwartz J, Minnis A, TRIO Study Team. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. J Int AIDS Soc. 2018;21(3):e25094.","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"435_CR18","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s10461-016-1565-9","volume":"21","author":"GJ Greene","year":"2017","unstructured":"Greene GJ, Swann G, Fought AJ, Carballo-Di\u00e9guez A, Hope TJ, Kiser PF, Mustanski B, Richard TD. Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among US men who have sex with men. AIDS Behav. 2017;21(5):1336\u201349.","journal-title":"AIDS Behav"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-022-00435-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-022-00435-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-022-00435-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T11:04:53Z","timestamp":1645787093000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-022-00435-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["435"],"URL":"https:\/\/doi.org\/10.1186\/s12981-022-00435-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-719332\/v1","asserted-by":"object"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"20 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of Washington Human Subjects Division (STUDY00007390). All participants provided verbal consent for study participation; written documentation of consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BH was an employee of RTI Health Solutions at the time this research was conducted. VCM has received investigator initiated research grants (to the institution) and consultation fees from Eli Lilly, Bayer, Gilead Sciences and ViiV.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}